Aarhus University Seal / Aarhus Universitets segl

Jørgen Frøkiær

Recommendations for biomarker identification and qualification in clinical proteomics

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Harald Mischak
  • ,
  • Günter Allmaier
  • ,
  • Rolf Apweiler
  • ,
  • Teresa Attwood
  • ,
  • Marc Baumann
  • ,
  • Ariela Benigni
  • ,
  • Samuel E Bennett
  • ,
  • Rainer Bischoff
  • ,
  • Erik Bongcam-Rudloff
  • ,
  • Giovambattista Capasso
  • ,
  • Joshua J Coon
  • ,
  • Patrick D'Haese
  • ,
  • Anna F Dominiczak
  • ,
  • Mohammed Dakna
  • ,
  • Hassan Dihazi
  • ,
  • Jochen H Ehrich
  • ,
  • Patricia Fernandez-Llama
  • ,
  • Danilo Fliser
  • ,
  • Jørgen Frøkiær
  • Jerome Garin
  • ,
  • Mark Girolami
  • ,
  • William S Hancock
  • ,
  • Marion Haubitz
  • ,
  • Denis Hochstrasser
  • ,
  • Rury R Holman
  • ,
  • John P A Ioannidis
  • ,
  • Joachim Jankowski
  • ,
  • Bruce A Julian
  • ,
  • Jon B Klein, Denmark
  • Walter Kolch
  • ,
  • Theo Luider
  • ,
  • Ziad Massy
  • ,
  • William B Mattes
  • ,
  • Franck Molina
  • ,
  • Bernard Monsarrat
  • ,
  • Jan Novak, Denmark
  • Karlheinz Peter
  • ,
  • Peter Rossing
  • ,
  • Marta Sánchez-Carbayo
  • ,
  • Joost P Schanstra
  • ,
  • O John Semmes
  • ,
  • Goce Spasovski
  • ,
  • Dan Theodorescu
  • ,
  • Visith Thongboonkerd
  • ,
  • Raymond Vanholder
  • ,
  • Timothy D Veenstra
  • ,
  • Eva Weissinger
  • ,
  • Tadashi Yamamoto
  • ,
  • Antonia Vlahou
  • Biomedical Radio Isotope Techniques
  • Teknisk Forvaltning
Clinical proteomics has yielded some early positive results-the identification of potential disease biomarkers-indicating the promise for this analytical approach to improve the current state of the art in clinical practice. However, the inability to verify some candidate molecules in subsequent studies has led to skepticism among many clinicians and regulatory bodies, and it has become evident that commonly encountered shortcomings in fundamental aspects of experimental design mainly during biomarker discovery must be addressed in order to provide robust data. In this Perspective, we assert that successful studies generally use suitable statistical approaches for biomarker definition and confirm results in independent test sets; in addition, we describe a brief set of practical and feasible recommendations that we have developed for investigators to properly identify and qualify proteomic biomarkers, which could also be used as reporting requirements. Such recommendations should help put proteomic biomarker discovery on the solid ground needed for turning the old promise into a new reality.
Original languageEnglish
JournalScience translational medicine
Volume2
Issue46
Pages (from-to)42
Number of pages46
DOIs
Publication statusPublished - 25 Aug 2010

    Research areas

  • Biological Markers, Humans, Mass Spectrometry, Proteomics

See relations at Aarhus University Citationformats

ID: 34152706